Roche presented early data on its Axelios 1 sequencing‑by‑expansion (SBX) nanopore platform at the AMP meeting, showing high concordance with Illumina NovaSeq in tumor‑normal whole‑genome comparisons. Hartwig Medical Foundation data indicated comparable SNV and indel detection and variant allele frequency concordance at high coverages. Roche highlighted automated library prep at batch sizes up to 32 samples and XOOS analysis tools that enable rapid ctDNA mutation detection and a concurrent variant‑and‑methylation assay under development. Early users cited sequencing speed as a differentiator, while emphasizing that quality parity with established platforms is essential for clinical adoption.